FDA approval for Zydus's new drug

Zydus Cadila has received final approval from the US regulator for Pyridostigmine Bromide Tablets


Pyridostigmine Bromide Tablets are used in the treatment of various neurological disorders

Zydus Cadila has received the final approval from the United States Food and Drug Administration (US FDA) to market Pyridostigmine Bromide Tablets USP, 60 mg.

The estimated sales in 2015 for Pyridostigmine Bromide Tablets USP, used in the treatment of various neurological disorders, is $27.9 million, as per IMS.

The group now has 100 approvals and has so far filed over 260 ANDAs since the commencement of the filing process in FY 2003-04.


Leave a Reply Sign in

Notify me of follow-up comments via e-mail address

Post Comment

Survey Box

Union Budget

Has Union budget 2017 addressed all requirements of healthcare industry?

Send this article by email